Combination of NKX3.1, PSA, uroplakin II and S100P is therefore proposed to be the favored immunohistochemical test to resolve the dilemma of distinguishing between bladder urothelial carcinomas and prostate adenocarcinoma. The gene discussed is S100P; the disease is bladder transitional cell carcinoma.